Trial Profile
A Double-Blind, Active-Controlled, Long-Term Safety Extension Study of Optimized Doses of Darusentan in Subjects With Resistant Hypertension Despite Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine (Protocol DAR-312-E) [EXTENSION OF 700013256]
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Darusentan (Primary) ; Guanfacine
- Indications Resistant hypertension
- Focus Therapeutic Use
- Acronyms DORADO-AC-EX
- Sponsors Gilead Sciences; Myogen
- 01 Apr 2014 New source identified and integrated (EudraCT2006-003548-42).
- 28 Mar 2014 New trial record